Navigation Links
China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
Date:9/2/2008

HARBIN, China, Sept. 2 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (AMEX: CSY), a leading fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it has received approval to list its common stock on the NASDAQ Global Market.

China Sky One expects to start trading on the NASDAQ Global Market on September 15, 2008, and that the last day of trading on the American Stock Exchange ("AMEX") will be September 12, 2008. The trading symbol for China Sky One's common stock on the NASDAQ Global Market will be "CSKI". The Company primarily sells its products in the People's Republic of China (PRC).

"We are very excited to list on NASDAQ and consider the change to be a significant milestone in China Sky One's development as a U.S. public company," commented Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One. "We are confident that the listing on NASDAQ will allow us to further enlarge our investor base and increase both our liquidity and visibility in the investment community."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

Mr. Yu-Bo Hao, Board Secretary

China Sky One Medical, Inc.

Tel: +86-0451-53994069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

Mr. Crocker Coulson, President

CCG Investor Relations

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Web site: http://www.ccgir.com

Mr. Richard Micchelli, Financial Writer

CCG Investor Relations

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web site: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
2. ORBIS and Alcon Train Chinas Next Generation of Sight-Savers
3. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
4. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
5. China Kangtai Cactus Biotech Announces Record Second Quarter Results
6. China Biologic Products Reports Second Quarter 2008 Results
7. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
8. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
9. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
10. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
11. China Medicine Announces Strong Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics ... leading maker of unmanned aircraft systems (UAS), are launching a joint program to ... effectively, and support educational outreach efforts. , AMA and DJI will collaborate on ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... Avomeen & ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann ... MichBio member organization. They provide an opportunity to interact with peers, make new connections ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
(Date:2/16/2017)... 16, 2017   Capricor Therapeutics, Inc. ... company developing first-in-class biological therapies for cardiac and ... elected to terminate its license agreement with the ... including Cenderitide. "Our decision to return ... prioritize our efforts to advance our core cell ...
Breaking Biology Technology:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
Breaking Biology News(10 mins):